The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog alfa), intended for on-demand treatment and control of bleeding events in adult patients with acquired hemophilia A, has received approval in China. This drug marks the first recombinant pig FVIII (rpFVIII) to be approved by both the FDA and EMA for acquired hemophilia A treatment. Susoctocog alfa boasts a structure and sequence homologous to human factor VIII (FVIII), and its resistance to inactivation by anti-human FVIII autoantibodies allows it to effectively replace human FVIII in hemostasis.
Takeda acquired susoctocog alfa through its $62 billion purchase of Shire in 2018, which had previously acquired the originator company Baxalta for $32 billion in 2016.- Flcube.com
